文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

血管生成素-1和-2在肺炎中的预后与致病作用

Prognostic and Pathogenic Role of Angiopoietin-1 and -2 in Pneumonia.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01
一句话结论肺炎患者血清血管生成素-2升高可预测28天死亡和住院时长,与CURB-65联合可提高预后准确性;血管生成素-1可能成为重症肺炎治疗靶点。

该研究在两个独立肺炎患者队列(n=148、n=395)中检测血清血管生成素水平,并结合人死后肺组织、内皮细胞、离体灌注通气小鼠肺及肺炎链球菌肺炎小鼠模型,探讨血管生成素-1/-2对肺血管屏障功能和炎症的预后与致病影响。结果显示肺炎患者血清血管生成素-1降低、血管生成素-2升高;社区获得性肺炎28天内死亡者血管生成素-2水平高于存活者;血管生成素-2联合CURB-65可提高对28天生存、ICU治疗和住院时长的预后准确性。体外和体内实验提示血管生成素-2增加内皮通透性,血管生成素-1可减轻肺炎链球菌溶血素诱导的通透性升高和炎症。作者认为血管生成素-2升高预测死亡和住院时长,血管生成素-1可能为重症肺炎提供治疗靶点。

要点

  • 肺炎患者血清血管生成素-1降低、血管生成素-2升高,与健康人相比有差异。
  • 社区获得性肺炎28天内死亡者血清血管生成素-2水平高于存活者。
  • 血管生成素-2联合CURB-65可提高对28天生存、ICU治疗和住院时长的预后准确性。
  • 体外实验中血管生成素-2增加内皮通透性,血管生成素-1减轻肺炎链球菌溶血素诱导的内皮通透性升高。
  • 小鼠肺炎模型中血管生成素-1治疗减轻炎症和通透性,作者认为其可能为重症肺炎治疗靶点。

适用人群与场景

  • 两个独立肺炎患者队列(n=148、n=395)的血清样本;另有人死后肺组织、内皮细胞、离体灌注通气小鼠肺及肺炎链球菌肺炎小鼠模型。

研究设计与关键结果

  • 研究类型为临床队列结合实验研究;两个独立肺炎患者队列样本量分别为n=148和n=395;肺炎患者较健康人血清血管生成素-1降低、血管生成素-2升高。
  • 社区获得性肺炎患者中,诊断后28天内死亡者血清血管生成素-2水平高于存活者。
  • 受试者工作特征分析显示,血管生成素-2血清水平联合CURB-65可提高对28天生存、ICU治疗和住院时长的预后准确性。
  • 体外实验中肺炎链球菌溶血素增强内皮血管生成素-2释放,血管生成素-2增加内皮通透性,血管生成素-1减轻肺炎链球菌溶血素诱导的内皮通透性升高。
  • 血管生成素-2敲低的离体灌注通气小鼠肺在肺炎链球菌溶血素刺激下通透性降低;肺炎链球菌感染小鼠肺组织血管生成素-2 mRNA表达升高、血管生成素-1 mRNA表达降低。
  • 小鼠肺炎模型中血管生成素-1治疗减轻炎症和通透性。

证据类型、等级与局限

  • 证据类型:临床队列研究结合体外细胞实验和动物实验;原文未报告证据等级或推荐强度。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为血管生成素-2血清水平升高可预测肺炎患者死亡和住院时长,联合CURB-65可提高预后准确性。
  • 作者认为血管生成素-1可能为重症肺炎提供治疗靶点。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

RATIONALE: During pneumonia, pathogen-host interaction evokes inflammation and lung barrier dysfunction. Tie2 activation by angiopoietin-1 reduces, whereas Tie2 blockade by angiopoietin-2 increases, inflammation and permeability during sepsis. The role of angiopoietin-1/-2 in pneumonia remains unidentified.

OBJECTIVES: To investigate the prognostic and pathogenic impact of angiopoietins in regulating pulmonary vascular barrier function and inflammation in bacterial pneumonia.

METHODS: Serum angiopoietin levels were quantified in pneumonia patients of two independent cohorts (n = 148, n = 395). Human postmortem lung tissue, pneumolysin- or angiopoietin-2-stimulated endothelial cells, isolated perfused and ventilated mouse lungs, and mice with pneumococcal pneumonia were investigated.

MEASUREMENTS AND MAIN RESULTS: In patients with pneumonia, decreased serum angiopoietin-1 and increased angiopoietin-2 levels were observed as compared with healthy subjects. Higher angiopoietin-2 serum levels were found in patients with community-acquired pneumonia who died within 28 days of diagnosis compared with survivors. Receiver operating characteristic analysis revealed improved prognostic accuracy of CURB-65 for 28-day survival, intensive care treatment, and length of hospital stay if combined with angiopoietin-2 serum levels. In vitro, pneumolysin enhanced endothelial angiopoietin-2 release, angiopoietin-2 increased endothelial permeability, and angiopoietin-1 reduced pneumolysin-evoked endothelial permeability. Ventilated and perfused lungs of mice with angiopoietin-2 knockdown showed reduced permeability on pneumolysin stimulation. Increased pulmonary angiopoietin-2 and reduced angiopoietin-1 mRNA expression were observed in Streptococcus pneumoniae-infected mice. Finally, angiopoietin-1 therapy reduced inflammation and permeability in murine pneumonia.

CONCLUSIONS: These data suggest a central role of angiopoietin-1/-2 in pneumonia-evoked inflammation and permeability. Increased angiopoietin-2 serum levels predicted mortality and length of hospital stay, and angiopoietin-1 may provide a therapeutic target for severe pneumonia.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Gutbier B, Neuhauß AK, Reppe K, et al. Prognostic and Pathogenic Role of Angiopoietin-1 and -2 in Pneumonia. Am J Respir Crit Care Med. 2018. PMID: 29447449. doi:10.1164/rccm.201708-1733OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。